This visit to Lundbeck’s R&D facilities in Valby offers a rare look inside how neuroscience innovation is conducted in practice. Through the tour across selected labs and research platforms, delegates will see how evidence is generated and how choices are made across the end-to-end R&D pathway, from scientific idea to treatment concepts that can ultimately reach patients.

Lundbeck is one of the few global pharmaceutical companies focused exclusively on brain health, with more than 70 years of neuroscience experience. This long-standing focus has built deep scientific capabilities, specialized platforms, and a sustained pipeline in neuroscience, anchored in a world-class R&D environment addressing complex and underserved brain disorders.

The visit will be a guided tour across Lundbeck’s key R&D departments, with short researcher perspectives at each stop and interactive dialogue throughout. It will bring to life the typical 12 to 15 year pathway from early discovery to solutions that can ultimately reach patients, and show how digital and data-driven methods, including AI and supercomputing, can accelerate learning, improve prioritization, and reduce uncertainty earlier in the process, supporting better outcomes, health system sustainability, and societal resilience.